文献速递乳腺癌

艾日布林联合吉西他滨对比紫杉醇联合吉西他滨一线治疗HER2阴性转移性乳腺癌的II期随机多中心研究

Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
PubMed 文献 · Eur J Cancer · 2017-11-05

该研究为前瞻性随机II期开放标签多中心试验,比较艾日布林联合吉西他滨(EG)与紫杉醇联合吉西他滨(PG)一线治疗HER2阴性转移性乳腺癌的疗效与安全性,共入组118例患者。结果显示两组6个月无进展生存率分别为72%和73%(P=0.457),总生存无显著差异(未达到 vs 21.2个月,P=0.2234),但EG组≥II级神经毒性显著低于PG组(13.6% vs 45.8%,P<0.0001)。

要点

  • EG方案一线治疗HER2阴性MBC的6个月PFS率与PG方案相似(72% vs 73%)。
  • EG组≥II级神经毒性发生率显著低于PG组(13.6% vs 45.8%)。
  • 两组总生存无显著差异,临床获益率分别为44%和49%。

核心结论

  • EG化疗在PFS方面与PG化疗具有相似的临床获益,但神经毒性更少。

研究设计与样本

  • 前瞻性随机II期开放标签两臂多中心研究,比较EG与PG一线治疗HER2阴性转移性乳腺癌。
  • 2015年3月至2016年3月共入组118例患者,随机分配至PG组(n=59)或EG组(n=59)。
  • 主要终点为无进展生存期(PFS),假设每臂6个月PFS率为70%;次要终点包括总生存期、神经病变量表、毒性和临床获益率。

主要发现

  • 6个月PFS率EG组为72%,PG组为73%(P=0.457)。
  • 总生存期两组无显著差异(未达到 vs 21.2个月,P=0.2234)。
  • 临床获益率EG组为44%,PG组为49%。
  • ≥II级神经毒性EG组为13.6%,PG组为45.8%(P<0.0001)。
  • 主要毒性为中性粒细胞减少和神经毒性。

关键数值与推荐

  • 6个月PFS率:EG组72%,PG组73%(P=0.457)。
  • 总生存期:EG组未达到,PG组21.2个月(P=0.2234)。
  • 临床获益率:EG组44%,PG组49%。
  • ≥II级神经毒性:EG组13.6%,PG组45.8%(P<0.0001)。

临床怎么用

  • 对于HER2阴性转移性乳腺癌一线化疗,EG方案可作为PG方案的替代选择,尤其关注神经毒性风险的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Paclitaxel plus gemcitabine (PG) combination chemotherapy is a preferred chemotherapeutic regimen for patients with metastatic breast cancer (MBC). Eribulin mesylate is a halichondrin non-taxane inhibitor of microtubule dynamics. A recent pooled analysis with eribulin showed improved overall survival (OS) in various MBC patient subgroups pretreated with anthracycline and taxane. Furthermore, eribulin may have less neurotoxicity than paclitaxel. PATIENTS AND METHODS: This study was a prospective randomised phase II, open-label, two-arm, multicentre study comparing eribulin plus gemcitabine (EG) with PG chemotherapy as a first-line treatment for patients with human epidermal growth factor receptor 2-negative MBC. We hypothesised that EG chemotherapy would not be inferior to PG chemotherapy. The primary end-point was progression-free survival (PFS), which was estimated to be 70% at 6 months for each arm. The secondary end-points were as follows: OS, neuropathic scale, toxicity and clinical benefit rate. RESULTS: A total of 118 patients (median age: 50, 24-66) were enrolled between March 2015 and March 2016 and were randomly assigned to PG (n = 59) or EG (n = 59) chemotherapy. The mean number of metastatic sites was 3 (range 1-8). The 6-month PFS rates for both arms were 72% for EG and 73% for PG (P = 0.457). There was no significant difference in OS between the two groups (not reached versus 21.2 months, P = 0.2234). The median number of chemotherapy cycles for both groups was 10 for EG and 8 for PG (range 2-32). Clinical benefit rates were 44% for EG and 49% for PG. Major toxicities were neutropenia and neurotoxicity. Grade II or above neurotoxicity was more common with PG than with EG (13.6% for EG versus 45.8% for PG, P < 0.0001). CONCLUSION: EG chemotherapy had similar clinical benefits to PG chemotherapy in terms of PFS but less neurotoxicity. TRIAL REGISTRATION: KCSG BR13-11; ClinicalTrials.gov, NCT02263495.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Park YH, Im SA, Kim SB, et al. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Eur J Cancer. 2017. PMID: 29100193. doi:10.1016/j.ejca.2017.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。